MDXG (MiMedx Group) Ending Cash Position: $159.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXG MiMedx Group Inc MDXG
57 GF Score
Price $4.26
GF Value $6.70
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group Ending Cash Position?

MiMedx Group MDXG +1.55% 57 Ending Cash Position is $159.8 Mil as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.70 (Significantly Undervalued). The stock has 2 warning signs investors should review.

MiMedx Group's Ending Cash Position for the quarter that ended in Mar. 2026 was $159.8 Mil.

MiMedx Group's quarterly Ending Cash Position increased from Sep. 2025 ($142.1 Mil) to Dec. 2025 ($166.1 Mil) but then declined from Dec. 2025 ($166.1 Mil) to Mar. 2026 ($159.8 Mil).

MiMedx Group's annual Ending Cash Position increased from Dec. 2023 ($82.0 Mil) to Dec. 2024 ($104.4 Mil) and increased from Dec. 2024 ($104.4 Mil) to Dec. 2025 ($166.1 Mil).

MiMedx Group Ending Cash Position Related Terms

MiMedx Group Ending Cash Position Historical Data

* Premium members only.

The historical data trend for MiMedx Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group Ending Cash Position Chart

MiMedx Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.08 65.95 82.00 104.42 166.12

MiMedx Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.43 118.87 142.08 166.12 159.77
MDXG
57GF Score
MiMedx Group Inc MDXG
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiMedx Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

MiMedx Group's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=104.416+61.705
=166.1

MiMedx Group's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=166.121+-6.348
=159.8

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $159.8 Mil mean?
MiMedx Group (MDXG) has a Ending Cash Position of $159.8 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MiMedx Group and its competitors.
Is MiMedx Group's Ending Cash Position too high?
MiMedx Group's current Ending Cash Position is $159.8 Mil. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Ending Cash Position compare to RGNX and ACHV?
MiMedx Group's Ending Cash Position of $159.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MiMedx Group and its competitors. MiMedx Group's current Ending Cash Position is $159.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.70, compared to a current price of $4.26 — trading 36.4% below its estimated fair value. The current Ending Cash Position is $159.8 Mil. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Ending Cash Position is $159.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $4.26 is trading 36.4% below its estimated GF Value™ of $6.70. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Ending Cash Position: $159.8 Mil
  • GF Value™: $6.70 vs. price of $4.26 (36.4% below fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score

Get the complete analysis for MDXG

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.26
Price
$6.70
GF Value